Placebo News and Research

RSS

Antidepressants ineffective in Alzheimer’s: Study

According to a new study published in the medical journal The Lancet on Tuesday, two antidepressants that are commonly given to Alzheimer's disease patients appear not only to be ineffective but may give side effects such as nausea and drowsiness. Researchers urged doctors to think twice before prescribing these drugs to Alzheimer's patients with depression.

20 Jul 2011

Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV

Pharmasset, Inc. announced today the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa 2a and ribavirin in subjects with hepatitis C virus (HCV) genotype 2 or 3 who have not been treated previously.

20 Jul 2011

Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

19 Jul 2011

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

Graceway Pharmaceuticals, LLC announced today that the Food and Drug Administration (FDA) has approved Zyclara Cream, 2.5% for the treatment of actinic keratoses, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses.

19 Jul 2011

Upsher-Smith initiates USL261 ARTEMIS1 Phase III study for seizure clusters in epilepsy patients

Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).

18 Jul 2011

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis.

18 Jul 2011

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

18 Jul 2011

Positive results from levomilnacipran Phase III study for major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of adults with major depressive disorder (MDD).

18 Jul 2011

QRxPharma seeks NDA approval for MoxDuo IR

QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.

18 Jul 2011

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

SEEK, a privately owned biopharmaceutical company specializing in immunology, announces today that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after just a single vaccine injection.

18 Jul 2011

Study indicates bi-directional relationships between alcohol and stress

Acute stress is thought to precipitate alcohol drinking. Yet the ways that acute stress can increase alcohol consumption are unclear. A new study investigated whether different phases of response to an acute stressor can alter the subjective effects of alcohol. Findings indicate bi-directional relationships between alcohol and stress.

16 Jul 2011

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses of up to over two years (at the latest time measured) in 7 of 8 evaluated patients following a fourth vaccination of VGX-3100, its investigational SynCon® DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

15 Jul 2011

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen today announced that the European Commission (EC) has granted marketing authorization for XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors.

15 Jul 2011

Transcept receives FDA Complete Response Letter for Intermezzo NDA

Transcept Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding the resubmitted New Drug Application (NDA) for Intermezzo.

15 Jul 2011

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint.

15 Jul 2011

Tocotrienol could help reduce stroke damage

Preventive supplementation with a natural form of vitamin E called tocotrienol could help reduce brain damage caused by strokes, researchers reported today at the 2nd International Conference on Tocotrienols and Chronic Diseases.

15 Jul 2011

UTHealth enrolls first patient in new stem cell therapy trial for ischemic stroke

The first Texas patient has been enrolled by researchers at The University of Texas Health Science Center at Houston in the country's first double-blind clinical trial studying the safety and efficacy of an innovative stem cell therapy that can be given up to 19 days after an ischemic stroke.

15 Jul 2011

Two new studies support use of PrEP for HIV prevention among heterosexual men and women

"Two new studies done in three African countries have shown for the first time that AIDS drugs taken daily can cut by more than half a person's chance of becoming infected with HIV through heterosexual intercourse," the Washington Post reports.

14 Jul 2011

UIC study reveals potential of lycopene in prostate cancer prevention among African American men

Lycopene, a red pigment that gives tomatoes and certain other fruits and vegetables their color, could help prevent prostate cancer, especially in African American men, according to new research at the University of Illinois at Chicago.

14 Jul 2011

Pre-exposure prophylaxis reduces risk of HIV infection

In a result that will fundamentally change approaches to HIV prevention in Africa, an international study has demonstrated that individuals at high risk for HIV infection who took a daily tablet containing an HIV medication - either the antiretroviral medication tenofovir or tenofovir in combination with emtricitabine - experienced significantly fewer HIV infections than those who received a placebo pill.

14 Jul 2011

Placebo News and Research

Antidepressants ineffective in Alzheimer’s: Study

Final SVR results from Pharmasset's PSI-7977 phase 2b study in HCV

Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

Upsher-Smith initiates USL261 ARTEMIS1 Phase III study for seizure clusters in epilepsy patients

FDA approves Shire's Lialda for maintenance of remission of ulcerative colitis

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

Positive results from levomilnacipran Phase III study for major depressive disorder

QRxPharma seeks NDA approval for MoxDuo IR

SEEK HIV-v vaccine demonstrates 90% reduction in HIV viral load

Study indicates bi-directional relationships between alcohol and stress

Inovio reports strong immune responses with VGX-3100 vaccine for cervical dysplasia and cancer

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Transcept receives FDA Complete Response Letter for Intermezzo NDA

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Tocotrienol could help reduce stroke damage

UTHealth enrolls first patient in new stem cell therapy trial for ischemic stroke

Two new studies support use of PrEP for HIV prevention among heterosexual men and women

UIC study reveals potential of lycopene in prostate cancer prevention among African American men

Pre-exposure prophylaxis reduces risk of HIV infection

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News